Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Increase in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,610,000 shares, a growth of 24.6% from the February 28th total of 3,700,000 shares. Approximately 5.7% of the company’s shares are short sold. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is currently 3.2 days.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Guggenheim restated a “buy” rating and set a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Piper Sandler began coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Finally, Jefferies Financial Group increased their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.63.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock traded down $0.17 on Wednesday, hitting $2.08. 2,467,876 shares of the company’s stock traded hands, compared to its average volume of 1,929,862. The company has a market capitalization of $286.94 million, a price-to-earnings ratio of -5.61 and a beta of 1.19. The company has a fifty day moving average of $2.83 and a two-hundred day moving average of $2.11. Compass Therapeutics has a one year low of $0.76 and a one year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CMPX. Rhumbline Advisers grew its stake in shares of Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after buying an additional 3,822 shares during the period. Invesco Ltd. grew its stake in Compass Therapeutics by 11.3% in the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after acquiring an additional 4,018 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Compass Therapeutics by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares during the period. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.